SKIN

Investigation Announcement: Kaskela Law LLC is investigating The Beauty Health Company (NASDAQ: SKIN) on behalf of its shareholders due to a significant decline in stock value, dropping over 60% since March 2024.

Legal Rights for Shareholders: Shareholders are encouraged to contact Kaskela Law LLC for information regarding potential violations of securities laws or fiduciary duties by the company's officers and directors.

Appointment Announcement: Stephen J. Fanning, a veteran in medical aesthetics with extensive experience, has been appointed to the Board of Directors of The Beauty Health Company, effective December 12, 2024.

Company Overview: The Beauty Health Company, known for its flagship brand Hydrafacial, focuses on delivering innovative skin health experiences and aims to enhance consumer confidence through personalized skincare solutions.

2024 Skintuition Report Highlights: The BeautyHealth Company released its 2024 Skintuition Report, showcasing a trend towards skinimalism where consumers prefer effective, non-invasive treatments that focus on hydration and overall skin health, as evidenced by the success of products like the Hydrafacial Hydralock HA Booster.

Future Trends in Skin Health: The report predicts a rise in the medicalization of beauty, an increase in informed consumers (particularly Gen Z and Millennials), a continued emphasis on tailored treatments, and a shift towards simpler skincare routines that prioritize efficacy over quantity.

Investigation Announcement: Glancy Prongay & Murray LLP is investigating The Beauty Health Company for potential violations of state laws by its directors and officers.

Contact Information: Shareholders seeking more information or with questions can contact Tom Kennedy at GPM, providing their details and share ownership.

Quarterly Performance: The Beauty Health Company reported a quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.12, with revenues of $78.8 million, which is down from $97.4 million year-over-year but slightly above estimates.

Market Outlook: Despite underperforming the market with a 43.4% decline this year, the company's future stock performance will depend on management's commentary and earnings estimate revisions, currently holding a Zacks Rank #3 (Hold).

Upcoming Financial Report: The Beauty Health Company will release its third quarter 2024 financial results on November 12, 2024, followed by an investor conference call at 4:30 p.m. ET, accessible via their investor relations website.

Company Overview: The Beauty Health Company specializes in skin health products, including Hydrafacial™, SkinStylus™, and Keravive™, and is dedicated to enhancing consumer confidence through personalized skin care experiences while being mindful of community and environmental impacts.

Hydrafacial Presentation at ASDS Meeting: The Beauty Health Company will present a video abstract on the efficacy and safety of Hydrafacial treatments combined with non-ablative fractional laser and intense pulsed light (IPL) at the American Society for Dermatologic Surgery meeting in October 2024.

Synergistic Effects of Treatments: The study highlights that Hydrafacial not only provides excellent results as a standalone treatment but also enhances skin quality and hydration when used alongside other advanced aesthetic procedures.

Hydrafacial Presentation at ASDS Meeting: The Beauty Health Company will present a video abstract on the efficacy and safety of Hydrafacial treatments combined with non-ablative fractional laser and IPL at the ASDS meeting in Orlando from October 17-20, 2024, highlighting their synergistic effects.

Significance of Findings: CEO Marla Beck emphasizes that this scientific data validates the observed benefits of combining Hydrafacial with other aesthetic treatments, enhancing skin quality and hydration while introducing a new treatment protocol for medical professionals.

New Executive Appointments: The Beauty Health Company has appointed Ron Menezes as Chief Revenue Officer and Carrie Caulkins as Chief Marketing Officer, effective October 15, 2024, to enhance its commercial leadership team and drive growth for the Hydrafacial brand.

Leadership Experience: Both executives bring extensive experience from the medical aesthetics industry, with Menezes focusing on global sales and business development, while Caulkins will lead marketing initiatives to strengthen brand awareness and market position.

Hydrafacial Glow Getter Scholarship Program: The Beauty Health Company has launched the Hydrafacial Glow Getter Scholarship program to support aspiring and licensed estheticians in their education and career advancement, offering a total of $60,000 in scholarships over two years, with applications opening on December 1, 2024.

Celebration of Estheticians: This initiative coincides with National Esthetician Day, where Hydrafacial will honor skin health professionals through various events and social media engagement, emphasizing their commitment to the growth and recognition of the esthetics profession.

Launch of Hydrafacial Hydralock HA Booster: The Beauty Health Company has introduced the Hydrafacial Hydralock HA Booster, a clinically tested formulation that enhances skin hydration by three times, reduces wrinkles by 63% after one treatment, and provides lasting moisture and glow.

Consumer Feedback and Efficacy: Developed with input from estheticians and consumers, the booster utilizes a blend of Triple Hyaluronic Acid Complex, Vitamin B5, and Fruit Extracts to address dehydrated and dull skin, with 94% of participants reporting improved hydration and brightness post-treatment.

Financial Performance Overview: The Beauty Health Company reported a 23% decline in revenue to $91 million for Q2 2024, primarily due to slower device sales and macroeconomic pressures, although consumable sales increased by 6.7%. The company anticipates third quarter net sales between $70 million and $80 million and expects to return to positive adjusted EBITDA in Q4.

Strategic Initiatives for Recovery: CEO Marla Beck outlined strategic initiatives focusing on sales execution, operational excellence, and financial discipline to address current challenges and improve profitability, including restructuring sales strategies, enhancing financing options for providers, and optimizing the product portfolio.

Analyst's Rating and Price Target: Analyst Oliver Chen from TD Cowen has maintained a Hold rating on Beauty Health (SKIN) with a lowered price target of $1.20, citing disappointing sales and EBITDA performance along with downgraded future projections.

Concerns Over Performance: The Delivery Systems segment is facing significant challenges, leading to a negative growth forecast for FY24, while the company’s efforts to introduce new financing options and affordable products have yet to show effectiveness in reversing the declining trend.

Financial Performance: The Beauty Health Company (SKIN) reported a revenue of $90.6 million for Q2 2024, a decline of 22.9% year-over-year, with an EPS of -$0.10 compared to $0.07 in the previous year, missing both revenue and EPS estimates.

Investment Insights: Zacks Investment Research highlighted seven elite stocks deemed likely for early price increases, emphasizing their historical performance of outperforming the market significantly since 1988.

ModivCare's Quarterly Performance: ModivCare reported a quarterly loss of $0.03 per share, significantly missing the Zacks Consensus Estimate of $0.81, and its revenues of $698.3 million also fell short of expectations, marking a 54.6% decline in shares since the beginning of the year.

Future Outlook and Industry Context: The company's earnings outlook remains mixed, with a current Zacks Rank of #3 (Hold), indicating expected performance in line with the market, while the Medical Services industry ranks in the bottom 41% of Zacks industries, potentially impacting stock performance.

Analyst Ratings Overview:

• 4 analysts have provided varying opinions on Beauty Health (NASDAQ:SKIN) in the past quarter, ranging from bullish to bearish sentiments. The table shows recent ratings and changes over the last 30 days.

Financial Performance of Beauty Health:

• Beauty Health's financial performance analysis includes insights on market capitalization, revenue growth challenges, net margin, return on equity (ROE), return on assets (ROA), and debt management.

• MultiMetaVerse Holdings Limited MMV saw a 224% increase in shares due to an acquisition agreement.
• GT Biopharma, Inc. GTBP rose by 146% following better-than-expected quarterly results.
• Tantech Holdings Ltd TANH jumped by 89.8%.
• Faraday Future Intelligent Electric Inc. FFIE gained 62.1% ahead of its financial report.
• CN Energy Group. Inc. CNEY surged by 58%.
• Scorpius Holdings, Inc. SCPX increased by 57.8%.
• NKGen Biotech, Inc. NKGN rose by 46% after clearance for a Phase 2 trial.
• Bruush Oral Care Inc. BRSH jumped by 41%.
• Rekor Systems, Inc. REKR gained 36% post-partnership announcement.
• MIRA Pharmaceuticals, Inc. MIRA rose by 34.3%.
• Scilex Holding Company SCLX gained 34%.
• Hims & Hers Health, Inc. HIMS rose by 30.5%.
• BYND Cannasoft Enterprises Inc. BCAN surged by 29.5%.
• Cheetah Mobile Inc. CMCM gained 24.3%.
• Concord Medical Services Holdings Limited CCM jumped by 23%.
• Wix.com Ltd. WIX rose by 21.6%.
• Sintx Technologies, Inc. SINT shares rose by 21.1%.
• Sutro Biopharma, Inc. STRO climbed by 17.6%.
• PTC Therapeutics, Inc. PTCT jumped by 17.2%.
• Cue Health Inc. HLTH gained 17.1%.
• NextDecade Corporation NEXT climbed by 16%.
• NuScale Power Corporation SMR rose by 15.5%.
• VinFast Auto Ltd. VFS gained 15%.
• Crown ElectroKinetics Corp. CRKN shares rose by 14.8%.
• Tellurian Inc. TELL gained 14%.
• Shineco, Inc. SISI shares climbed by 10.2%.
• Independent Bank Group, Inc. IBTX gained 8.5%.
• Doximity, Inc. DOCS surged by 5.1%.

• Akoustis Technologies, Inc. AKTS fell by 53.8%.
• Cheetah